Pharmaceutical More and more global pharmaceutical companies are refusing to test new drugs in Russia. In the first five months, the number of approvals for clinical trials for drugmakers from the European Union and the USA in Russia has decreased by 18.5%, while for Russian manufacturers it grew by almost 90%, mainly due to generics, reports The Pharma Letter’s local correspondent. 15 June 2022